While modulating Bcl-2 pathways can be effective in MS, future research should aim to provide greater clarification and to design precision-based drugs capable of neuroprotective effects.

Among 5 255 randomized patients, 374 (7.1%) had LTBI and received preventive treatment, most commonly isoniazid (82.1%) and rifampicin (11.8%). From Year 1-5 (after ~98% of LTBI+ patients completed preventive treatment), transaminase elevations were generally similar among LTBI+ and LTBI- patients. The absence of observed TB risk in guselkumab-treated patients suggests IL-23 inhibitors may be better treatment options than TNFi in high-risk patients, including those in TB-endemic regions.

Detection was carried out by multiple reaction monitoring mode using the transitions m/z 634.3→184.2 for golvatinib and m/z 650.3→200.2 for golvatinib N-oxide. Further study demonstrated that CYP3A4 was the principal enzyme involved in metabolizing golvatinib. To the best of our knowledge, this is the first report combining ultra-high-performance liquid chromatography-tandem MS (UHPLC-MS/MS) with UHPLC-Quadrupole-Orbitrap-HRMS for profiling golvatinib metabolism in vitro, thereby laying a foundation for subsequent pharmacokinetic study.

P2, N=42, Recruiting, Brigham and Women's Hospital | Trial completion date: Mar 2025 --> Jan 2027 | Trial primary completion date: Sep 2024 --> Jun 2026

P1/2, N=20, Completed, NexThera Co., Ltd. | Active, not recruiting --> Completed | N=30 --> 20

P2, N=30, Not yet recruiting, Georgetown University

P4, N=2174, Active, not recruiting, Duke University | Recruiting --> Active, not recruiting

This suggests that our findings reflect a heretofore unknown connection between G6PD polymorphisms and the 3D genomic organization that controls VEGFR blocker-induced expression of DNA/histone demethylases. Potential effects include up-regulation of genes encoding proteins, which evoke cell migration and inflammation within the lungs and contribute to the pathogenesis of PVD.

P2, N=53, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2028 --> Jun 2028

These findings indicate that combined curcumin and doxorubicin induce apoptosis primarily through JNK-dependent MAPK signaling, accompanied by stress-associated cellular responses.

Moreover, they effectively promote CRT exposure, HMGB1 release, and ATP secretion in 4T1 cells. Furthermore, in a murine breast cancer model, CMCS-D + C/NPs significantly upregulate the expression of proteins such as CD8 and Caspase-3, cytokines (IFN-γ and IL-6), and Granzyme B, demonstrating favorable antitumor efficacy.

P2, N=53, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027